Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alessandro Morabito

Showing results (91-100 of 198) with videos related to

Pageof 20
Sort By:
Eclinicalmedicine|July 1, 2021
Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung: Final analysis of the randomised phase 3 LUX-Lung 8 trialGlenwood D Goss, Manuel Cobo, Shun Lu, et al.
Diagnostics (Basel, Switzerland)|January 21, 2023
Immunotherapy Assessment: A New Paradigm for RadiologistsVincenza Granata, Roberta Fusco, Sergio Venanzio Setola, et al.
The American Journal of Surgical Pathology|November 6, 2019
Heterogeneity of PD-L1 Expression in Lung Mixed Adenocarcinomas and Adenosquamous CarcinomasFederica Zito Marino, Giulio Rossi, Marco Montella, et al.
American Journal of Clinical Pathology|May 20, 2014
CD90 expression in atypical meningiomas and meningioma metastasisGiosuè Scognamiglio, Antonio D'Antonio, Giulio Rossi, et al.
Frontiers in Oncology|June 14, 2021
Angiogenesis Inhibitors in Small Cell Lung CancerAgnese Montanino, Anna Manzo, Guido Carillio, et al.
International Journal of Molecular Sciences|May 11, 2024
The Impact of Inadequate Exposure to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors on the Development of Resistance in Non-Small-Cell Lung Cancer CellsDaniela Frezzetti, Vincenza Caridi, Laura Marra, et al.
Breast Cancer Research and Treatment|November 30, 2004
Safety and activity of the combination of pegylated liposomal doxorubicin and weekly docetaxel in advanced breast cancerAlessandro Morabito, Domenico Gattuso, Simonetta Chiara Stani, et al.
Breast Cancer Research and Treatment|July 20, 2006
Randomized Phase II Trial of weekly paclitaxel alone versus trastuzumab plus weekly paclitaxel as first-line therapy of patients with Her-2 positive advanced breast cancerGiampietro Gasparini, Massimo Gion, Luigi Mariani, et al.
Clinical Lung Cancer|January 14, 2015
Cisplatin/Pemetrexed Followed by Maintenance Pemetrexed Versus Carboplatin/Paclitaxel/Bevacizumab Followed by Maintenance Bevacizumab in Advanced Nonsquamous Lung Cancer: The GOIM (Gruppo Oncologico Italia Meridionale) ERACLE Phase III Randomized TrialDomenico Galetta, Saverio Cinieri, Salvatore Pisconti, et al.
International Journal of Molecular Sciences|July 16, 2020
Unproductive Effects of ALK Gene Amplification and Copy Number Gain in Non-Small-Cell Lung Cancer. ALK Gene Amplification and Copy Gain in NSCLCFederica Zito Marino, Gerardo Botti, Gabriella Aquino, et al.
Pageof 20

Showing results (91-100 of 198) with videos related to

Sort By:
Pageof 20
Eclinicalmedicine|July 1, 2021
Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung: Final analysis of the randomised phase 3 LUX-Lung 8 trialGlenwood D Goss, Manuel Cobo, Shun Lu, et al.
Diagnostics (Basel, Switzerland)|January 21, 2023
Immunotherapy Assessment: A New Paradigm for RadiologistsVincenza Granata, Roberta Fusco, Sergio Venanzio Setola, et al.
The American Journal of Surgical Pathology|November 6, 2019
Heterogeneity of PD-L1 Expression in Lung Mixed Adenocarcinomas and Adenosquamous CarcinomasFederica Zito Marino, Giulio Rossi, Marco Montella, et al.
American Journal of Clinical Pathology|May 20, 2014
CD90 expression in atypical meningiomas and meningioma metastasisGiosuè Scognamiglio, Antonio D'Antonio, Giulio Rossi, et al.
Frontiers in Oncology|June 14, 2021
Angiogenesis Inhibitors in Small Cell Lung CancerAgnese Montanino, Anna Manzo, Guido Carillio, et al.
International Journal of Molecular Sciences|May 11, 2024
The Impact of Inadequate Exposure to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors on the Development of Resistance in Non-Small-Cell Lung Cancer CellsDaniela Frezzetti, Vincenza Caridi, Laura Marra, et al.
Breast Cancer Research and Treatment|November 30, 2004
Safety and activity of the combination of pegylated liposomal doxorubicin and weekly docetaxel in advanced breast cancerAlessandro Morabito, Domenico Gattuso, Simonetta Chiara Stani, et al.
Breast Cancer Research and Treatment|July 20, 2006
Randomized Phase II Trial of weekly paclitaxel alone versus trastuzumab plus weekly paclitaxel as first-line therapy of patients with Her-2 positive advanced breast cancerGiampietro Gasparini, Massimo Gion, Luigi Mariani, et al.
Clinical Lung Cancer|January 14, 2015
Cisplatin/Pemetrexed Followed by Maintenance Pemetrexed Versus Carboplatin/Paclitaxel/Bevacizumab Followed by Maintenance Bevacizumab in Advanced Nonsquamous Lung Cancer: The GOIM (Gruppo Oncologico Italia Meridionale) ERACLE Phase III Randomized TrialDomenico Galetta, Saverio Cinieri, Salvatore Pisconti, et al.
International Journal of Molecular Sciences|July 16, 2020
Unproductive Effects of ALK Gene Amplification and Copy Number Gain in Non-Small-Cell Lung Cancer. ALK Gene Amplification and Copy Gain in NSCLCFederica Zito Marino, Gerardo Botti, Gabriella Aquino, et al.
Pageof 20